CRISPR Therapeutics vs Editas Medicine
CRISPR Therapeutics vs Editas Medicine, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CRISPR Therapeutics is on 64/100 and Editas Medicine on 42/100.
Where each one leads
CRISPR Therapeutics
- our overall score: 64/100 against 42/100
- agent readiness: 44/100 against 39/100
- funding raised: $547M against $210M
Editas Medicine
Leads on none of the measures we hold for both companies.
At a glance
| Measure | CRISPR Therapeutics | Editas Medicine |
|---|---|---|
| What it is | Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology. | A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases. |
| Category | Biotechnology, Gene Editing, Therapeutics, Pharmaceuticals | Biotech, MedTech, Genomics, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2013 | 2013 |
| Headquarters | Zug, Switzerland | Cambridge, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | CRISPR Therapeutics | Editas Medicine |
|---|---|---|
| Employees | Not published | 185 |
| Total funding | $547M | $210M |
| Latest round | Series B | Series B |
| LinkedIn followers | Not published | 52,616 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CRISPR Therapeutics | Editas Medicine |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 64/100 | 42/100 |
| Traction | 40/100 | 60/100 |
| Team | 70/100 | Not published |
| Search visibility | 13/100 | 27/100 |
| Quality | 88/100 | 45/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (44/100) | F (39/100) |
| Domain ratingLink authority, 0-100 | 67/100 | 61/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CRISPR Therapeutics | Editas Medicine |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Jquery | Jquery, Tailwind CSS, Bootstrap |
| Analytics | Google Analytics 4 | Google Tag Manager |
CRISPR Therapeutics vs Editas Medicine: common questions
Which is better, CRISPR Therapeutics or Editas Medicine?
On our 0-100 score CRISPR Therapeutics rates higher (64/100 against 42/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.
How do CRISPR Therapeutics and Editas Medicine compare on the numbers?
CRISPR Therapeutics leads on our overall score (64/100 against 42/100), agent readiness (44/100 against 39/100), funding raised ($547M against $210M).
Read the full CRISPR Therapeutics review and pricing or the Editas Medicine review and pricing. You can also browse other CRISPR Therapeutics alternatives we track.